Matthew Barcus
Stock Analyst at Chardan Capital
(2.37)
# 2,609
Out of 4,996 analysts
21
Total ratings
25%
Success rate
21.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $2.41 | +314.94% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $54.31 | -50.29% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.80 | +779.51% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $16.23 | +97.17% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.60 | +36,597.25% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.40 | +164.71% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $11.59 | -30.97% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $2.41
Upside: +314.94%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $54.31
Upside: -50.29%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.80
Upside: +779.51%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $16.23
Upside: +97.17%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.60
Upside: +36,597.25%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.40
Upside: +164.71%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $11.59
Upside: -30.97%